Adiponectin–leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance DOI Creative Commons
Chia‐Wen Lu, Kuen‐Cheh Yang,

Yu‐Chiao Chi

et al.

Annals of Medicine, Journal Year: 2023, Volume and Issue: 55(1), P. 634 - 642

Published: Feb. 15, 2023

Lean Non-alcoholic Fatty Liver Disease (NAFLD) shares a similar disease burden to those of their overweight counterparts and should be detected early. We hypothesized that the adiponectin-leptin ratio (AL ratio) could good marker for early detection lean NAFLD independent insulin resistance.A total 575 adults without diabetes were enrolled in community-based study. The subjects stratified into controls, NAFLD, simple overweight/obesity groups according body mass index (BMI) ultrasonographic fatty liver indicators. Serum adiponectin leptin levels measured by enzyme-linked immunosorbent assay. Multivariate logistic regression analyses performed estimate odds having relation tertiles serum AL concentration after adjustment. Receiver operating characteristic (ROC) applied evaluate diagnostic performance NAFLD.The mean age participants was 42.8 ± 11.5 years. Comparing with highest versus lowest tertile 0.28(95%CI: 0.12-0.69) Putting ratio, BMI, triglyceride, AST/ALT diagnosis ROC 0.85 (95% CI: 0.82-0.88), 0.83 CI 0.78-0.87) 0.86 081-0.91) all women men, respectively. (p < .001).The study revealed biomarker distinguish patients from controls resistance. [AQ3]Key messagesThe prevalence non-alcoholic increases globally is related diseases metabolic dysfunctions. subset early.Adiponectin-leptin associated severity steatosis predictor obese better than each single adipokine. To date, there no investigation explores specifically relationship between ratio.Our found sole regardless resistance NAFLD. Having adjustment age, sex, current smoking, exercise habits, HOMA-IR AST/ALT. (0.85; 95% 0.82-0.88). Further rigorous necessary promptly performed.

Language: Английский

Biomarkers for Health Functional Foods in Metabolic Dysfunction-Associated Steatotic Liver Disorder (MASLD) Prevention: An Integrative Analysis of Network Pharmacology, Gut Microbiota, and Multi-Omics DOI Open Access

Heng Yuan,

Eun-Soo Jung,

Soo-Wan Chae

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(18), P. 3061 - 3061

Published: Sept. 11, 2024

Metabolic dysfunction-associated steatotic liver disorder (MASLD) is increasingly prevalent globally, highlighting the need for preventive strategies and early interventions. This comprehensive review explores potential of health functional foods (HFFs) to maintain healthy function prevent MASLD through an integrative analysis network pharmacology, gut microbiota, multi-omics approaches. We first examined biomarkers associated with MASLD, emphasizing complex interplay genetic, environmental, lifestyle factors. then applied pharmacology identify food components beneficial effects on metabolic function, elucidating their action mechanisms. identifies evaluates halting or reversing development disease in stages, as well that can evaluate success failure such strategies. The crucial role microbiota its metabolites prevention homeostasis discussed. also cover state-of-the-art omics approaches, including transcriptomics, metabolomics, integrated analyses, research preventing MASLD. These advanced technologies provide deeper insights into physiological mechanisms HFF development. concludes by proposing approach developing HFFs targeting prevention, considering Korean regulatory framework. outline future directions bridge gap between basic science practical applications narrative provides a foundation researchers industry professionals interested support health. Emphasis placed maintaining balance focusing early-stage intervention

Language: Английский

Citations

9
The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis DOI Creative Commons

Qiong Lv,

Hua-Shan Zhao

Annals of Medicine, Journal Year: 2024, Volume and Issue: 56(1)

Published: Jan. 22, 2024

Objective While studies have documented how metabolic dysfunction-associated steatotic liver disease (MASLD) can contribute to cardiovascular (CVD), whether MASLD is associated with myocardial infarction (MI) remains debateable. Herein, we systematically reviewed published articles and performed a meta-analysis determine the relationship between MI risk.

Language: Английский

Citations

8
Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review DOI Creative Commons
Arun J. Sanyal, Mansoor Husain,

Crystel Diab

et al.

American Heart Journal Plus Cardiology Research and Practice, Journal Year: 2024, Volume and Issue: 41, P. 100386 - 100386

Published: March 24, 2024

The burden of cardiovascular disease (CVD) in patients with metabolic dysfunction-associated steatohepatitis (MASH) is poorly characterized, particularly

Language: Английский

Citations

8
Pediatric Non-Alcoholic Fatty Liver Disease (NAFLD): Trends, Mortality, and Socioeconomic Disparities in the U.S., 1998–2020 DOI Creative Commons
Paul Wasuwanich,

Joshua M. So,

Mustafa Sadek

et al.

Children, Journal Year: 2025, Volume and Issue: 12(1), P. 71 - 71

Published: Jan. 8, 2025

We aim to describe the changing inpatient epidemiology of NAFLD in U.S. and identify major risk factors associated with mortality disease among hospitalized pediatric patients. Hospitalization data from 1998-2020 National Inpatient Sample were utilized. ICD-9 ICD-10 codes used patients (age less than 18 years old) NAFLD, for analyzed by logistic regression. identified 68,869 hospitalizations involving NAFLD. Among those, 970 (1.4%) died during hospitalization. rates have been rapidly increasing 1998 2020 (incidence rate ratio (IRR): 1.07; 95% CI: 1.06-1.07; p < 0.001). There was a significant difference based on type hospital (rural, non-teaching urban, or teaching urban) (p 0.05). Coagulopathy significantly increased odds mortality, while age ≥ 12 years, diabetes obesity decreased Sex, race/ethnicity, hepatitis B, C, HIV, IV drug use not mortality. Our study has shown ever hospitalization populations well as Further studies should be performed more this patient population are collected.

Language: Английский

Citations

1
Assessing the causal relationships between human blood metabolites and the risk of NAFLD: A comprehensive mendelian randomization study DOI Creative Commons
Ziwei Guo, Tingyu Zhang, Zhangjun Yun

et al.

Frontiers in Genetics, Journal Year: 2023, Volume and Issue: 14

Published: March 28, 2023

Background: Non-alcoholic fatty liver disease (NAFLD) is a associated with obesity, insulin resistance, type 2 diabetes mellitus (T2DM), and metabolic syndrome. The risk factors for NAFLD have not been identified. Metabolic dysfunction has found to be an important factor in the pathogenesis progression of NAFLD. However, causal impact blood metabolites on unclear. Methods: We performed two-sample Mendelian randomization (MR) study. A genome-wide association study (GWAS) 7824 participants provided data 486 human metabolites. Outcome information was obtained from large-scale GWAS meta-analysis NAFLD, which contained 8,434 cases 770,180 controls Europeans. inverse variance weighted (IVW) model chosen as primary MR analysis approach, followed by sensitivity analyses such heterogeneity test, horizontal pleiotropy leave-one-out analysis. In addition, we replication, meta-analysis, pathway further conducted colocalization deeply reflect causality. Results: After rigorous genetic variant selection, IVW, analysis, two known were identified being development [biliverdin: OR = 1.45; 95% CI 1.20-1.75; p 0.0001; myristoleate: 0.57; 0.39-0.83; 0.0030]. Conclusion: By combining genomics metabolomics, our findings provide new perspective underlying mechanisms implications screening prevention

Language: Английский

Citations

18
Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease DOI Open Access
Laura Valenzuela‐Vallejo, Despina Sanoudou, Christos S. Mantzoros

et al.

Journal of Personalized Medicine, Journal Year: 2023, Volume and Issue: 13(5), P. 830 - 830

Published: May 14, 2023

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic disease, and related to fatal non-fatal liver, metabolic, cardiovascular complications. Its non-invasive diagnosis effective treatment remain an unmet clinical need. NAFLD a heterogeneous that commonly present in context of metabolic syndrome obesity, but not uncommonly, may also be without abnormalities subjects with normal body mass index. Therefore, more specific pathophysiology-based subcategorization (FLD) needed better understand, diagnose, treat patients FLD. A precision medicine approach for FLD expected improve patient care, decrease long-term outcomes, develop better-targeted, treatments. We herein based on our recently proposed subcategorization, which includes metabolic-associated (MAFLD) (i.e., obesity-associated (OAFLD), sarcopenia-associated (SAFLD, lipodystrophy-associated (LAFLD)), genetics-associated (GAFLD), multiple/unknown causes (XAFLD), combined (CAFLD) as well advanced stage fibrotic (FAFLD) end-stage (ESFLD) subcategories. These other advances, whole, are enable only improved quality life, considerable reduction healthcare system costs associated FLD, along options treatments near future.

Language: Английский

Citations

18
Circulating hormones in biopsy-proven steatotic liver disease and steatohepatitis: A Multicenter Observational Study DOI
Laura Valenzuela‐Vallejo, Pavlina Chrysafi, Matina Kouvari

et al.

Metabolism, Journal Year: 2023, Volume and Issue: 148, P. 155694 - 155694

Published: Sept. 25, 2023

Language: Английский

Citations

18
Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial DOI Open Access
Mazen Noureddin,

Shaharyar M. Khan,

Francisco R. Portell

et al.

˜The œLancet. Gastroenterology & hepatology, Journal Year: 2023, Volume and Issue: 8(12), P. 1094 - 1105

Published: Oct. 5, 2023

Language: Английский

Citations

17
Decellularized extracellular matrix materials for treatment of ischemic cardiomyopathy DOI Creative Commons
Wei Liu, Xiangmei Zhang,

Xiaokai Jiang

et al.

Bioactive Materials, Journal Year: 2023, Volume and Issue: 33, P. 460 - 482

Published: Nov. 29, 2023

Ischemic cardiomyopathy (ICM) affect millions of patients globally. Decellularized extracellular matrix materials (dECM) have components, microstructure and mechanical properties similar to healthy cardiac tissues, can be manufactured into various forms implantable biomaterials including injectable hydrogels or epicardial patches, which been extensively reported attenuate pathological left ventricular remodeling maintain heart function. Recently, dECM medical devices for ICM treatment approved clinical use studied in trials, exhibiting considerable translation potential. Cells, growth factors other bioactive agents incorporated with different improve the therapeutic outcomes. In addition, more detailed aspects biological effects mechanisms are being revealed. This review summarized recent advances from variable sources repair, extraction matrix, cell integration, smart manufacturing patch materials, their applications. Besides, this provides an outlook on cutting-edge development directions field.

Language: Английский

Citations

17
Loss of hepatic PPARα in mice causes hypertension and cardiovascular disease DOI
Olufunto O. Badmus, Zachary A. Kipp, Evelyn A. Bates

et al.

AJP Regulatory Integrative and Comparative Physiology, Journal Year: 2023, Volume and Issue: 325(1), P. R81 - R95

Published: May 22, 2023

The leading cause of death in patients with nonalcoholic fatty liver disease (NAFLD) is cardiovascular (CVD). However, the mechanisms are unknown. Mice deficient hepatocyte proliferator-activated receptor-α (PPARα) ( Ppara HepKO ) exhibit hepatic steatosis on a regular chow diet, making them prone to manifesting NAFLD. We hypothesized that mice might be predisposed poorer phenotypes due increased fat content. Therefore, we used and littermate control fed diet avoid complications high-fat such as insulin resistance adiposity. After 30 wk standard male exhibited elevated content compared littermates measured by Echo MRI (11.95 ± 1.4 vs. 3.74 1.4%, P < 0.05), triglycerides (1.4 0.10 0.3 0.01 mM, Oil Red O staining, despite body weight, fasting blood glucose, levels being same controls. also displayed mean arterial pressure (121 4 108 2 mmHg, impaired diastolic function, cardiac remodeling, enhanced vascular stiffness. To determine controlling increase stiffness aorta, state-of-the-art PamGene technology measure kinase activity this tissue. Our data suggest loss PPARα induces alterations aortas reduce tropomyosin receptor kinases p70S6K kinase, which contribute pathogenesis NAFLD-induced CVD. These indicate protects system through some as-of-yet undefined mechanism.

Language: Английский

Citations

14